Find an expert

Dr Andrew Brooks is the Group Leader of the Cytokine Receptor Signalling Group at the University of Queensland Diamantina Institute (UQ DI) within the Translational Research Institute. Andrew completed his Honours research on Flaviviruses in 1996 at the Department of Microbiology and Immunology at James Cook University and then moved to the Department of Biochemistry to study Dengue Virus where he completed his PhD in 2002. He then moved to St Jude Children’s Research Hospital in Memphis, TN, USA where he researched the role of Epstein-Barr Virus in B-cell lymphomagenesis. He then joined the research group headed by Prof Michael Waters at the Institute for Molecular Bioscience, UQ in 2006 and subsequently began his independent research group at UQ DI in 2014. Andrew’s research interests are in cytokine receptors, cell signalling, oncogenesis, and immunology. His current research focus is on the molecular mechanisms of class I cytokine receptor activation including the growth hormone receptor (GHR), thrombopoietin receptor (TpoR/MPL), IL-7 receptor, and IL-6 receptor (IL-6R). In addition, he is investigating the regulation of inflammation by HLA-G. His research has led to publications in journals including Science, Blood, Hepatology, Oncogene, Nature Cell Biology, and PNAS. He has been the secured of over $12 million in research and commercialisation funding from sources including NHMRC, ARC, Innovation Connections, and Merck. He has a number of national and international collaborations, a scientific founder of a start-up company, and is an Editorial Board member for the Journal Cancers and Human Cell. He was previously a committee member of Australian Early-Mid Career Researchers Forum (AEMCRF) launched by the Australian Academy of Science.

Dr Gordon’s research is focused on the formation and maintenance of the blood and lymphatic vascular systems. Vessels form complex branched networks that supply oxygen and nutrients to all body tissues. The signals controlling blood vessel expansion, identity and migration are all downstream of a single, common complex at the cell surface, yet exactly how this diverse range of functions is differentially regulated, depending on the physiological need, remains unknown.

The specific focus of Dr Gordon’s research is to determine the precise molecular signals that control cell adhesion within the vessel wall the surrounding environment. If the signals controlling cell adhesion become deregulated, normal vessel growth and function is lost. This contributes to the progression of a wide range of human diseases, including cancer growth and metastasis, diabetic eye disease and stroke. Dr Gordon aims to use novel biological models, biochemical assays and imaging techniques to better understand vessel biology, which will enable improved treatment of disease and aid in the development of vascularised, bioengineered organs.

Dr Gordon received her Bachelor of Science (2005) and PhD (2011) from The University of Adelaide, after which she undertook six years of postdoctoral studies at Yale University in the USA and Uppsala University in Sweden. With the support of an ARC DECRA Fellowship, Dr Gordon relocated to IMB in 2017 to establish her independent research career as an IMB Fellow. In 2019, she was appointed as Group Leader of the Vessel Dynamics Laboratory.

A/Prof Sumaira Hasnain graduated with her PhD in December 2010 from The University of Manchester and is an Associate Professor at Mater Research with a team of eight researchers. A/Prof Hasnain was the first globally to demonstrate that immunity can modulate protein production in secretory cells in infection and chronic diseases. Her long-term vision has been to characterise these novel immune factors and manipulate them therapeutically using pre-clinical models of immune-driven pathologies.

A/Prof Hasnain holds a patent for targeted immunotherapy in metabolic disease which has led to the formation of a spin-off company, Jetra Therapeutics and venture capitalist funding. She has a rapid upward trajectory in research, evident by extensive body of high-quality publications including in Nature Medicine, Nature Communications, Journal of Experimental Medicine, Oncogene and Gastroenterology. She has been awarded more than $9 million in competitive funding and recently gained the National Health and Medical Research Council L1 Investigator Grant. A/Prof Hasnain has won 21 awards to date, including the Commercialisation award from The University of Queensland in 2022 and the Gastroenterological Society for Australasia; Lawrie Powell Award in 2023.

A/Prof Landsberg's undergraudate and Honours studies, majoring in Chemistry, were completed at Central Queensland University and the CSIRO (JM Rendel laboratories) before he moved to the University of Queensland to study a PhD in Biochemistry (awarded 2003). He then moved to a postdoctoral position at the Institute for Molecular Bioscience, spending time as a Visiting Scientist at Harvard Medical School (2008) and securing promotion to Senior Research Officer upon his return to IMB in 2009. He additioanlly spent time as a Visiting Scientist at the Victor Chang Cardiac Research Institute in 2010 and 2011.

In 2016, he joined UQ's School of Chemistry and Molecular Biosciences as a Group Leader in Cryo-EM and Macromolecular Structure and Senior Lecturer in Biochemistry and Biophysics, where he was promoted to Associate Professor in 2019. He has secured >$13.5M in competitive research funding since 2012, including major grants from the Australian Research Council and National Health and Medical Research Council. He his research has been presented at over 70 national and international conferences and research institutions.

Junxian Lim is an accomplished molecular biologist at the Institute for Molecular Bioscience. With a strong background in cell biology, protein biochemistry, and pharmacology, he has established himself in the field. Collaborating with researchers at universities, institutions, as well as international industry partners like AstraZeneca and Sosei Heptares, he has contributed significantly to advancing scientific knowledge.

Throughout his doctoral studies, Junxian authored seven ground-breaking studies focused on the development of novel bioactive inhibitors targeting immune cells and inflammatory diseases. These contributions have paved the way for innovative approaches to drug development. Utilizing his expertise, he has successfully developed and characterized a diverse range of protein and cellular assays that enable in-depth investigations into immunity and inflammation. His research findings have been published in prestigious scientific journals, including Nature Communications, Cell Reports, Journal of the American Chemical Society, Diabetes, Journal of Medicinal Chemistry, and the British Journal of Pharmacology. His work has been highly cited, reflecting its impact and significance within the scientific community.

Recognized for his outstanding mentoring abilities, Junxian has supervised or co-supervised the research of two completed PhD students, six completed MPhil students, and three completed Honours students. The success of his former students is a testament to his dedication and guidance. They continue to excel and actively contribute to research endeavours around the world, spanning countries such as Australia, Singapore, Korea, India, Japan, and China.

Beyond his research and mentoring achievements, Junxian actively participates in the scientific community. He serves on the editorial boards of esteemed journals like Journal of Translational Medicine, Frontiers in Molecular Biosciences and Biology. This involvement allows him to stay at the forefront of scientific advancements and contribute to the dissemination of knowledge within his field.

Dr Melanie Robitaille is a Senior Post-Doctoral Researcher working with the Calcium Signalling in Therapeutics Team (CaSTT) in the School of Pharmacy. This team specializes in the development and application of novel methodologies and cellular assays in drug discovery, including the use of genetically encoded indicator for high-content imaging in live cells.

Her interests are to elucidate how calcium signals are remodelled in disease states, to identify calcium transporters as new therapeutic targets and to develop molecular and cellular screening tools to be used in drug development programs. She has an established profile in cellular and molecular biology, with high expertise in plasmid cloning, lentiviral transduction and the use of CRISPR/Cas9 to modulate gene expression.

​Dr Tosolini is a cell biologist with a focus at the intersection of axonal transport, neurotrophic factors, motor neurons and skeletal muscle, in the context of motor neuron disease (MND)/amyotrophic lateral sclerosis (ALS). His research to date has focused on utilising the connectivity between skeletal muscle and motor neurons for the enhanced delivery of therapeutic agents to the spinal cord (e.g., viral-mediated gene therapy). Building upon these foundations, his postdoctoral training focused on defining the axonal transport dynamics in a number of different experimental conditions, including stimulation with different neurotrophic factors (e.g., BDNF, GDNF), α motor neuron subtypes (i.e., fast motor neurons vs slow motor neurons), and alterations to such factors in MND/ALS pathology.

Dr Tosolini has joined the laboratories of A/Prof. Shyuan Ngo (AIBN) and Dr. Derek Steyn (SBMS) to undertake a novel project looking at assessing a novel therapeutic compound in mouse models of ALS, and in as well as in ALS patient-derived muscle cultures. This project is in collaboration with Dr. Giovanni Nardo at Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

​Dr Tosolini completed his PhD in 2015 in the discipline of Anatomy at the School of Medical Sciences, University of New South Wales (UNSW). His PhD project focused on characterising the connectivity between various skeletal muscles and their innervating motor neuron pools, to optimally deliver agents (e.g., retrograde tracers, virus) to the spinal cord motor neurons via retrograde axonal transport. For the work produced in his PhD, Dr Tosolini was awarded a place on the Faculty of Medicine's Dean's List.

In 2016, Dr Tosolini joined the Schiavo Laboratory at University College London (UCL), UK as a Post-Doctoral Research Associate to undertake a project focused on: 1) understanding factors influencing axonal transport dynamics in distinct in vitro and in vivo models of motor neuron disease (MND)/amyotrophic lateral sclerosis (ALS), and 2) revealing the signalling elements governing neuronal trans-synaptic transfer.

In 2020, Dr Tosolini was awarded a Junior Non-Clinical Post-Doctoral Fellowship by the Motor Neuron Disease Association, UK to expand his work on evaluating axonal transport dynamics in mouse models of motor neuron disease (MND) as well as in diverse human induced pluripotent stem cell (hiPSC)-derived motor neurons. This project is a direct continuation of my post-doctoral training in the Schiavo laboratory, and included a novel collaboration with Prof. Rickie Patani (Francis Crick Institute, London, UK), to evaluate axonal transport dynamics of diverse organelles in mouse and human models of MND/ALS.